31 results about "Anabolism" patented technology

The invention provides an application of a compound Aldometanib in preparation of a medicine for preventing and treating immune-related adverse reactions and diseases. Based on the first discovered prevention and treatment effects of Aldometanib on fatal immune hepatitis, immune myocarditis, pneumonia and enteritis, the invention specifically discloses application of Aldometanib in preparation of drugs for prevention and treatment of immune-related adverse reactions and diseases, and the main mechanism is that Aldometanib activates immune cells AMPK, enhances catabolism of immune cells, promotes immune cell apoptosis, promotes immune cell apoptosis, and improves immune cell apoptosis. The anabolism of the immune cells is inhibited, so that the expression of effector factors of the immune cells is controlled, and inflammatory factor storm is inhibited. Aldometanib has the effects of preventing the occurrence of immune-related adverse reactions and diseases, and inhibiting the attack levels of the immune-related adverse reactions and diseases, so that non-lethal and lethal injuries caused by an immune system to body organs are reduced.

The invention discloses lactobacillus crispatus for relieving senescence by promoting collagen synthesis and a metagen of the lactobacillus crispatus, and belongs to the technical field of microorganisms and medicines. The lactobacillus crispatus CCFM1462 metagen provided by the invention has a good skin anti-aging effect, the content of collagen is increased, meanwhile, the skin moisture can be increased, and the skin oxidation resistance can be improved. Specifically, the enzyme activity of MMP-3 and MMP-1 of HSF cells can be inhibited in vitro by thallus lysate, and the content of COL I and COL III and the enzyme activity of LH1 can be improved in vitro from fermentation of supernate; the enzyme activity of MMP-1 and MMP-3 can be inhibited by orally taking inactivated thalli; the self-fermented supernate is orally taken, so that the enzyme activity of LH1 and LOX can be improved, the enzyme activity of MMP-3 can be reduced, and the anabolism of collagen can be regulated and controlled.

The invention discloses application of aloe polysaccharide in regulation and control of mitochondrial energy metabolism, and belongs to the field of new application of aloe polysaccharide. The aloe polysaccharide can regulate mitochondrial energy metabolism to be converted into anabolism, promote the content of protein and amino acid in cells and promote wound healing. The preparation method of the aloe polysaccharide comprises the following steps: removing two ends of fresh aloe barbadensis leaves, and soaking the fresh aloe barbadensis leaves with pure water for 1-2 days; washing with water and removing skin to obtain aloe gel to be ground; shearing the aloe vera gel to be ground in an automatic gel grinding device to finish gel grinding, so as to obtain aloe polysaccharide feed liquid; and putting the aloe polysaccharide feed liquid into a stirring tank, stirring at 4-15 DEG C, carrying out light treatment for at least 24 hours, and then collecting the aloe polysaccharide pervaporation membrane on the surface of the liquid in a high-temperature membrane forming tank at 75-95 DEG C, thereby obtaining the aloe polysaccharide pervaporation membrane.

Embodiments of the present invention disclose a genetically modified cell that accelerates tissue repair by overexpressing CXCR4. This motile cell can be administered to subjects in need, enhancing tissue regeneration compared to unmodified cells. The cell may include various progenitor cell lines and demonstrates low NF-Kb pathway activity, which suppresses catabolic activity and promotes anabolism in inflammatory environments. The invention also encompasses methods of treatment using these cells, compositions containing them, and kits for their delivery.

The invention discloses application of chlorella in preparation of a medicine for treating osteoarthritis, in-vivo experiments and in-vitro experiments prove that chlorella can maintain a chondrocyte metabolism steady state, inhibit expression of chondrocyte extracellular matrix catabolism-related genes and proteins, and inhibit osteoarthritis. The expression of genes and proteins related to chondrocyte extracellular matrix anabolism is promoted, and by injecting a chlorella solution into a knee joint cavity, the effects of relieving and improving OA pain are achieved; furthermore, polydopamine is used for modifying the chlorella to obtain the polydopamine-coated chlorella Ch (at) P with a photothermal effect, and the Ch (at) P not only maintains the biological activity of the chlorella, but also has the effect of delaying cartilage degeneration and OA process due to the photothermal effect under near infrared (NIR) irradiation.

The invention discloses a corn kernel linoleic acid content negative regulation gene ZmRPL31 as well as a mutant and application thereof, and a candidate gene ZmRPL31 closely related to linoleic acid anabolism in a high-linoleic acid corn selfing line YM-2 is successfully screened based on BSA (Bovine Serum Albumin) population construction and RNA-seq transcriptome analysis. Corn B73 pollen is treated through an ethyl methanesulfonate mutagenesis technology, and a rpl31 homozygous mutant strain is successfully constructed. GC-MS detection is carried out on the linoleic acid content of a homozygous mutant strain, and it is confirmed for the first time that the ribosomal protein gene ZmRPL31 has a negative regulation effect on synthesis of corn linoleic acid. Wherein the linoleic acid content of the rpl31-22 homozygous mutant strain in grain tissues is remarkably increased by 43.7% compared with that of wild type corn B73, and meanwhile, the linoleic acid content of the rpl31-22 homozygous mutant strain in leaves in the seedling stage is remarkably increased by 23.5% compared with that of the wild type corn B73.

The present invention discloses the application of forsythin in the preparation of a medicament for treating intervertebral disc degeneration, belonging to the field of medical technology. In the study of intervertebral disc degeneration, it is found that forsythin can significantly inhibit the increase in catabolism and the decrease in anabolism of nucleus pulposus cells during the progression of intervertebral disc degeneration, and also has a significant inhibitory effect on the activation of the NF-κB pathway and the increase in ROS, thereby regulating the synthesis and catabolism of the extracellular matrix and cell apoptosis. Moreover, through verification, it is found that it has a therapeutic effect in a rat model of intervertebral disc degeneration, confirming that it also has a rescue effect on intervertebral disc degeneration in vivo.

The application discloses creatine composition for improving exercise endurance and strength, and a preparation method and application thereof. The creatine composition comprises creatine, black pepper extract and oyster peptide. The scheme has the effects of significantly enhancing energy systems, promoting anabolism, inhibiting catabolism, reducing oxidative damage and accelerating recovery through the combination of components, and can be effectively used for improving exercise endurance and strength.

This invention belongs to the field of biomedical technology, specifically involving the application of the MRPL41 gene / protein in the preparation of drugs for treating age-related sarcopenia. This invention is the first to demonstrate that MRPL41 is a key rate-limiting factor in the assembly of mitochondrial ribosomes in aging muscle satellite cells, establishing it as a core target for the treatment of age-related sarcopenia. Overexpression of MRPL41 can promote the assembly of mitochondrial 55S holoenzymes, improve the translation efficiency of mitochondrial-encoded proteins, repair mitochondrial dysfunction at its source, thereby promoting muscle repair, improving muscle atrophy, and achieving the treatment of age-related sarcopenia. This invention provides a precise microscopic target for the treatment of age-related sarcopenia, overcoming the limitations of existing clinical therapies (such as hormone replacement and simple nutritional supplementation) due to significant side effects and "anabolism resistance," providing a new direction for the development of innovative drugs specifically for the treatment of age-related sarcopenia, and has excellent application prospects.

Provided is a promoter, which has a nucleotide sequence shown in SEQ ID NO. 1. The promoter is obtained by means of rationally designing the promoter of a dapA gene, has obviously reduced transcriptional activity and can be used for the weakened expression of microorganism genes. Substituting the original promoters of the dapA gene, a ddh gene, an ilvA gene, a tdcB gene and a gltA gene in Corynebacterium glutamicum by using the promoter enables the expression levels of these genes to be significantly reduced, the carbon metabolic in a recombinant microorganism constructed thereby flows more to a threonine anabolism pathway, and the recombinant microorganism has a significantly improved production of threonine in comparison with an original strain and has good growth performance.

Disclosed in the present invention are a 4-sulfamoylphenylpropanamide compound and the use thereof. Provided in the present invention are a compound as represented by formula (I), an isotopically labeled substance thereof, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of the pharmaceutically acceptable salt thereof, or a prodrug thereof. The compound can promote ALP expression in osteoblasts, exhibit a relatively good activity for promoting osteoblast differentiation, and has potential therapeutic effects in promoting bone anabolism and treating bone-related diseases.

The invention belongs to the technical field of biological medicines, and particularly relates to application of rubimaillin in preparation of a medicine for delaying intervertebral disc degeneration. Compared with the limitations of inexact conservative treatment effect and high surgical intervention risk in the prior art, the invention reveals for the first time that rubimaillin (MO) can effectively regulate and control a PI3K-AKT / NF-kappa B signal channel through targeted inhibition of EGFR phosphorylation, alleviates nucleus pulposus cell metabolic disorder caused by an inflammatory microenvironment from the source, significantly improves the expression of anabolism markers, and provides a new application for the treatment of the inflammatory microenvironment. The compound inhibits the release of catabolic enzymes and inflammatory factors, delays the processes of cell aging and apoptosis, and shows a clear effect of delaying the progress of IDD in animal and cellular levels. Compared with the traditional treatment, the traditional Chinese medicine composition has the advantages of good effect, low side effect and the like, so that a new way can be provided for preventing and treating the IDD.

The invention discloses an application of a ZmCPK28 gene or an encoded protein thereof in regulation and control of crop carbohydrate anabolism, and belongs to the technical field of gene engineering. By observing the phenotypes of an overexpression material and a mutant material of the ZmCPK28 gene under different nitrogen concentration conditions, the phenotype and the overground part biomass of the wild type B73-329 are superior to those of the mutant material and have no obvious difference from those of the overexpression material. Meanwhile, the ZmCPK28 gene has the function of regulating and controlling carbohydrate synthesis of corn seedlings, for example, overexpression of the ZmCPK28 gene can improve the content of sucrose and trehalose and reduce the content of glucose and fructose, and a theoretical basis is provided for clarification of the effect of ZmCPK28 in corn growth and development and sugar anabolism.

The invention discloses a screening method and application of phaffia rhodozyma strains. The phaffia rhodozyma strain HSASTA is obtained through screening evolution and has characteristic sequences of five key enzyme genes in the anabolism process of astaxanthin. When the phaffia rhodozyma is used for producing the astaxanthin, the yield can reach 8000 mg / kg or above. The strain can be applied to various industrial fields of health care products, food, food additives and the like, and has wide development and application prospects.

The invention discloses an Eriocheir sinensis ELOVL7 gene and application thereof, the nucleotide sequence of the Eriocheir sinensis ELOVL7 gene is as shown in SEQ ID NO: 1, and the amino acid sequence of protein encoded by the Eriocheir sinensis ELOVL7 gene is as shown in SEQ ID NO: 2. The Eriocheir sinensis ELOVL7 gene sequence is successfully obtained through a PCR technology for the first time, the function of the ELOVL7 gene is verified through an in-vitro experiment, it is proved that the gene serves as an elongase gene to play a role in the Eriocheir sinensis fatty acid synthesis process, the function of promoting LC-PUFA synthesis is achieved, a foundation is laid for studying the LC-PUFA anabolism mechanism of the Eriocheir sinensis, and the Eriocheir sinensis ELOVL7 gene has a good application prospect. And a reference is provided for the functional research of other crustacean ELOVL7.

The invention provides a tandem gene for biosynthesizing astaxanthin in rape seeds, an expression cassette and an expression method, and belongs to the technical field of gene engineering. The invention provides a tandem gene for biosynthesis of astaxanthin, and four carotenoid anabolism genes are firstly constructed into the tandem gene for a biosynthesis path of astaxanthin. The four carotenoid anabolism genes are driven based on the rape seed specific NAPIN promoter to construct an astaxanthin biosynthesis path in the rape seeds and synthesize the astaxanthin, so that the biosynthesis efficiency of the astaxanthin is improved; the expression of the astaxanthin biosynthetic gene and the accumulation of the astaxanthin in the seeds do not influence the growth, development and reproduction of the rape; in addition, fat-soluble carotenoid and astaxanthin are naturally integrated with grease in the rape seeds, and astaxanthin rapeseed oil is directly used as a product, so that the activity of astaxanthin is maintained, and the later astaxanthin extraction production cost can be reduced.

The invention discloses a long-acting parathyroid hormone receptor stimulant fusion protein and application thereof. The fusion protein can inhibit the activity of RANKL and promote PTHR-mediated bone anabolism, and comprises a first arm and a second arm, the first arm comprises a functional region targeting RANKL and an Fc region, and the second arm comprises a functional region capable of activating PTHR and an Fc region. The long-acting parathyroid hormone receptor stimulant fusion protein has the advantages of better drug effect, more lasting effect, better safety, higher structural stability, higher expression quantity and the like, and the comprehensive performance of the long-acting parathyroid hormone receptor stimulant fusion protein is superior to that of the existing or potential treatment means such as teriparatide, PEG-PTH, anti-RANKL monoclonal antibody, romomonoclonal antibody or a control sample synPTH-alpha RANKL-1.

The invention discloses mannosylerythritol lipid produced by fermentation of an aphid yeast XM01 strain as well as a fermentation method and application of the mannosylerythritol lipid, and belongs to the technical field of microorganisms. The invention provides a fermentation method using the aphid torulopsis XM01 strain, through compounding and screening of a carbon source, a secondary metabolism integration pathway of sugar alcohol is effectively activated, meanwhile, synthesis of mannosylerythritol lipid MELs is effectively promoted, and the yield reaches up to 82.21 g / L; the invention further provides the MELs prepared by using the safflower oil as the first carbon source, the C10 content in a fatty acid side chain of the MELs accounts for 80% or above, and the MELs is good in emulsifying property, has antioxidant and anti-inflammatory capacities, can effectively inhibit candida albicans and promote cell proliferation, and has reference significance in application of preparing biological preparations in cosmetics and drugs by using the MELs; according to the MELs prepared by the invention, the technical problems of emulsification control and metabolic balance in the amplification process are solved by decoupling thallus growth and a product anabolism path through a time sequence.

The invention discloses application of lactobacillus helveticus CCFM1440 in regulating and controlling anabolism of host collagen to relieve senescence, and belongs to the technical field of microorganisms and the technical field of medicines. The metagen of the lactobacillus helveticus CCFM1440 provided by the invention has a good skin anti-aging effect, and can improve the moisture and elasticity of the skin, improve the antioxidant capacity of the skin, reduce the inflammation level of the organism and relieve aging. Specifically, the enzyme activity of LH1 and LOX of HSF cells and the content of COLIII are improved in vitro and in vitro through thallus lysate; the inactivated thalli are orally taken, so that the enzyme activity of LH1, P4H and LOX is improved, the enzyme activity of MMP-1 and MMP-3 is inhibited, and the collagen content is increased; the self-fermented supernate is orally taken, so that the enzyme activity of MMP-3 can be inhibited, the content of IL-6 and CRP can be reduced, and the skin moisture can be improved.

The invention discloses a 4-sulfamoyl phenylpropanamide compound and an application of the 4-sulfamoyl phenylpropanamide compound. The invention provides a compound as shown in a formula (I), an isotope label thereof, a solvate thereof, a pharmaceutically acceptable salt thereof, a solvate of the pharmaceutically acceptable salt thereof or a prodrug thereof. The compound can promote ALP expression of osteoblasts, has good promotion activity on differentiation of osteoblasts, and has potential treatment effects in the aspects of promotion of bone anabolism and treatment of bone related diseases.

The invention discloses application of a SiMC1 gene in regulation and control of anabolism of millet carotenoid, and belongs to the technical field of genetic engineering breeding. According to the invention, the SiMC1 gene for regulating and controlling metabolism of carotenoid in millet is screened, and the nucleotide sequence of the SiMC1 gene is shown as SEQ ID NO. 1. Experimental results show that compared with a wild plant (WT), the millet yellowness and the carotenoid content of the SiMC1 gene knockout strain (KO) are remarkably increased, the SiMC1 gene negatively regulates synthesis of millet carotenoid, and the SiMC1 gene is a potential efficient millet breeding gene and can be used for improving the appearance character and the eating quality of millet. Gene modification targets and theoretical basis are provided for screening and cultivating high-quality millet varieties, and new millet germplasm which has both appearance and taste and is rich in natural antioxidant nutritional ingredients is expected to be obtained.

The invention belongs to the technical field of genetic engineering, and particularly relates to application of a citrus ERF transcription factor CitERF92 in regulating and controlling the content of citrus polymethoxylated flavonoids. Through transient expression of CitERF92 in rock candy orange peel, it is found that compared with a control group, the content of citrus flavones, nobiletin, 5, 6, 7, 4 '-tetramethoxyflavone, heptamethoxyflavone and tangeretin in an overexpression group is up-regulated to different degrees, and it is indicated that accumulation of citrus polymethoxyflavone can be promoted through transient overexpression of CitERF92. Therefore, the transcription factor CitERF92 participates in and regulates synthesis of the polymethoxylated flavonoids, and is of great significance in perfecting a regulation network of anabolism of the citrus flavonoids and realizing industrialized synthesis of the polymethoxylated flavonoids.

The invention discloses a method for producing fidaxomicin through fermentation. From the angle of strengthening fidaxomicin anabolism flow, the fidaxomicin synthesis precursor substance valine is purposefully added, so that the anabolism flow is guided to fidaxomicin, and the biosynthesis of the lipiarmycin A4 impurity is competitively reduced. According to the method for controlling the lipiarmycin A4 impurity, provided by the invention, the lipiarmycin A4 impurity is controlled from a fermentation source, and the preparation times of downstream procedures are reduced, so that the use of an organic solvent is reduced, and the production cost is reduced.

The polypeptide feed is prepared from the following raw materials in percentage by mass: 35%-40% of a plant crude extract, 35%-45% of a protein source, 5%-8% of microbial flora and 15%-20% of a fermentation auxiliary material, wherein the plant extract is prepared from the following raw materials in percentage by mass: 50% of an astragalus membranaceus crude extract, 30% of a codonopsis pilosula crude extract and 20% of an angelica sinensis crude extract. The feed contains various plant and animal-derived amino acids, can supplement various nutrients in animal bodies, maintain amino acid balance, and is beneficial to enhancing protein fat absorption, promoting muscle and fat growth and improving meat quality and flavor, and meanwhile, the rich peptide contains various beneficial bacteria and free fatty acids, so that vasoactive intestinal peptide causes vasodilatation of mesentery, and the meat quality and flavor are improved. Protease and digestive enzymes are secreted in quantity, intestinal tract movement is enhanced, digestive absorption and anabolism of the body are enhanced, and therefore growth of the body is promoted.

The invention relates to the technical field of aquatic product quality safety, in particular to a saxitoxin risk formation chain characterization monitoring system, which comprises a data acquisition module, a data processing module, a data processing module and a display module, the risk chain association module is used for constructing a multi-factor toxin association mechanism model, analyzing and quantifying influence weights of environmental factors through a causal inference algorithm and a random forest weight, and identifying key regulation points and threshold values of toxin synthesis; the risk chain mechanism analysis module carries out deduction through a digital twin simulation platform and a dynamic Bayesian network, simulates the dynamic change of a toxin anabolism pathway under different environment scenes, and obtains a risk formation chain and a risk change rule thereof; and the risk monitoring and intervention module constructs a global risk prediction model to obtain a risk level, obtains an emergency scheme from the emergency decision library according to the risk level and the toxin type, and performs intervention according to the emergency scheme. Therefore, the problems of monitoring lag, unknown causality, low intervention efficiency and the like are solved.

The present invention relates to a pharmaceutical composition for preventing or treating muscle diseases, comprising an extract of Brassica juncea as an active ingredient. Inhibitory activity against myotube cell atrophy, a muscle anabolic factor expression promoting activity, and an effect of recovering from dexamethasone-induced enhancement of muscle cell catabolism and inhibition of anabolism of the Brassica juncea extract have been analyzed, and the effects of the Brassica juncea extract on recovery of reduced muscle tissue size, weight and muscle fiber size, biostability, a serum LDH level recovery effect, and an effect of reducing CK and creatinine levels in animal models have been analyzed, and thus it has been identified that the Brassica juncea extract can be used for preventing or treating sarcopenia or muscle atrophy.

The invention belongs to the field of biological pharmacy, and relates to a herbal hydrogel delivery system and a preparation method and application thereof. The invention successfully constructs and systematically verifies a herbaceous hydrogel delivery system (Rh-Gel at CCM at PM) with cartilage targeting, the platform efficiently delivers BRD4 PROTAC through mesoporous silicon nanoparticles (PM) coated with cartilage cell membrane (CCM), and the degradation of BRD4 is remarkably promoted, so that the histone acetylation activation of Nav1.7 is inhibited, and the transcriptional expression of Nav1.7 is regulated and controlled. The mechanism effectively improves the inflammation, catabolism enhancement and mitochondrial dysfunction of cartilage cells induced by TNF-alpha, recovers anabolism and energy steady state, and finally significantly relieves cartilage degeneration and joint dysfunction in a DMM and MIA induced OA mouse model.

The invention relates to an application of an indoleamine 2, 3-dioxygenase 1 inhibitor in preparation of a medicine for treating cancer cachexia. The indoleamine 2, 3-dioxygenase 1 is determined as a core therapeutic target of cancer cachexia for the first time, and it is proved that palmatine hydrochloride shows an exact therapeutic effect in cell and animal models through a multi-channel synergistic mechanism of metabolic reprogramming, protein degradation inhibition, anabolism signal recovery and muscle regeneration promotion. And sufficient experimental basis and theoretical support are provided for clinical transformation.

The invention relates to the technical field of fertilizers, in particular to a method for preparing a functional microbial organic fertilizer preparation from Chinese herbal medicines. According to the invention, the gynostemma pentaphylla dregs, the lindera aggregata dregs and the buckwheat straws are adaptively selected as complementary stacking materials and are stacked by a layered alternating method before the first turning; meanwhile, trichoderma harzianum, bacillus subtilis and streptomyces microflavus are constructed to serve as a composite flora, the flora is added step by step to prepare a microbial fermentation material with the high nutrient content, and the microbial fermentation material is used for preparing an organic fertilizer preparation finished product and has a positive effect on growth and quality improvement of crops. In addition, the marigold extract, the artemisia annua extract and the origanum vulgare extract are also added to construct a multi-aspect nematode-resistant system with the functions of repelling, protecting, blocking anabolism and damaging the integrity of a membrane, so that the prepared microbial organic fertilizer preparation can effectively have an excellent nematode-resistant effect.

The invention belongs to the technical field of gene engineering, and discloses a gene engineering strain for de novo synthesis of NMN by using a mixed carbon source. The method comprises the following steps: performing overexpression on a glucose-6-phosphate 1-dehydrogenase gene, a 6-phosphogluconate dehydrogenase gene, an aspartate transaminase gene, a phosphoenolpyruvate carboxylase gene and a deletion glycerol kinase gene on E.coli N12, and performing overexpression on a point mutation glycerol kinase gene and a deletion glycerol dehydrogenase gene on the E.coli N12 to obtain E.coli N12-7; an expression vector is used for serially expressing a nicotinic acid nucleotide pyrophosphorylase gene, an NAD synthetase gene, a quinoline synthase gene and an aspartic acid oxidase gene, and a recombinant plasmid P-1 is introduced into E.coli N12-7 to obtain the recombinant protein. According to the present invention, the escherichia coli NMN anabolism is systematically modified to achieve the de novo synthesis of the NMN by using the glucose and the glycerol as the mixed carbon source, and other substrates do not need to be added during the fermentation process so as to save the fermentation cost;